CMEonHIV.com is dedicated to providing online CME presentations (slides with voiceover) on HIV/AIDS for healthcare professionals given by local and international experts to keep you up-to-date on the ongoing developments in the field.
Conference
"HSV and HIV- A Troublesome Synergy?" Dr. Dr. Robert Patrick O'Brien (biography) English - 2004-06-28 - 36 minutes
(36 slides)
Summary : In this presentation, Dr. O’Brien takes a look at the increasingly recognized problem presented by HSV/HIV co-infection. HSV infection is one of the most common sexually transmitted illnesses in the world. 20% to 25% of the North American population is infected. Men who have sex with men (MSM) have a higher rate of HSV infection (50% in non-HIV-infected persons) and this rate is increased even further in HIV-infected MSM. Moreover, an increasing amount of genital herpes is due to HSV-1 infection, especially among MSM.
Genital herpes is underdiagnosed, according to Dr. O’Brien, in part because the majority of cases are either asymptomatic or present with atypical symptoms.
Dr. O’Brien reveals how HSV infection acts as a cofactor for HIV transmission, acquisition and progression. HIV effects on the natural history of HSV infection are also discussed.
In this presentation, the relative benefits and draw-backs of different HSV diagnostic modalities are presented as well as the treatment options for HSV alone and HSV in the setting of HIV co-infection.
Dr. O’Brien concludes his talk with a discussion of the potential benefits of treating HSV infection in both HIV+ and HIV- individuals and the need for objective data to support these theoretical advantages.
Learning objectives : After viewing this presentation, participants will be able to discuss:
- The magnitude of the Genital Herpes epidemic in the North America.
- The role of HSV in potentiating the transmission, acquisition, and progression of HIV.
- The role of HIV in promoting the spread of HSV and in altering its Natural History.
- The potential benefit to both HIV-infected and non-infected individuals of treating HSV infection and the evidence for these.
Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T, Douglas JM Jr, Paavonen J, Morrow RA, Beutner KR, Stratchounsky LS, Mertz G, Keene ON, Watson HA, Tait D, Vargas-Cortes M; Valacyclovir HSV Transmission Study Group.Once-daily valacyclovir to reduce the risk of transmission of genital herpes.N Engl J Med. 2004 Jan 1;350(1):11-20.
USER ACKNOWLEDGES AND AGREES THAT ALL DECISIONS MADE WITH THE ASSISTANCE OR USE OF THE SOFTWARE AND/OR THE WEBSITE AND/OR BASED ON CONTENT FOUND HEREIN WILL BE EXCLUSIVELY THE RESPONSIBILITY OF THE USER.
